Dihydroergotamine as a pharmacologic euglycemic clamp in the surgically traumatized rabbit

Kurt A. Mossberg, Heinrich Taegtmeyer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We assessed the utility of a pharmacologic euglycemic clamp technique by examining the metabolic and hemodynamic changes brought about by administration of dihydroergotamine (DHE) prior to anesthesia and operative trauma in the rabbit. New Zealand white rabbits received an intramuscular injection of 0.15 mg DHE/kg body weight 20 minutes before general anesthesia and minor surgical trauma, which consisted of carotid artery and jugular vein catheterizations followed by femoral artery and vein cannulations. Arterial blood was sampled every 20 minutes and assayed for glucose, lactate, nonesterified fatty acids (NEFA), and insulin. Rates of hindlimb skeletal muscle glucose uptake (Rg) and blood flow were determined 2 hours after the initial administration of DHE. DHE did not produce any effects on heart rate, blood pressure, blood flow, and Rg when compared with control animals. Liver glycogen levels were significantly higher after DHE treatment (140 ± 31.4 v 34 ± 9.6 μmol/g dry weight, P<.01). Those animals receiving DHE had significantly lower and more stable plasma glucose levels than untreated animals (ranges, 5 to 9 v 7 to 22 μmol/mL plasma) and circulating NEFA were also lower and less variable (ranges, 0.1 to 1.0 v 0.1 to 2.0 μEq/mL plasma). The results show that DHE prevents stress-induced hyperglycemia in vivo in the rabbit without altering glucose uptake by skeletal muscle. The technique provides control over circulating glucose levels during the study of skeletal muscle glucose uptake without apparent negative physiologic effects.

Original languageEnglish (US)
Pages (from-to)594-599
Number of pages6
JournalMetabolism
Volume40
Issue number6
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Dihydroergotamine
Glucose Clamp Technique
Rabbits
Glucose
Skeletal Muscle
Nonesterified Fatty Acids
Catheterization
Liver Glycogen
Femoral Vein
Intramuscular Injections
Jugular Veins
Wounds and Injuries
Femoral Artery
Hindlimb
Carotid Arteries
Hyperglycemia
General Anesthesia
Lactic Acid
Anesthesia
Heart Rate

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Dihydroergotamine as a pharmacologic euglycemic clamp in the surgically traumatized rabbit. / Mossberg, Kurt A.; Taegtmeyer, Heinrich.

In: Metabolism, Vol. 40, No. 6, 1991, p. 594-599.

Research output: Contribution to journalArticle

Mossberg, Kurt A. ; Taegtmeyer, Heinrich. / Dihydroergotamine as a pharmacologic euglycemic clamp in the surgically traumatized rabbit. In: Metabolism. 1991 ; Vol. 40, No. 6. pp. 594-599.
@article{096a76429cd540098b9f98190a6390d6,
title = "Dihydroergotamine as a pharmacologic euglycemic clamp in the surgically traumatized rabbit",
abstract = "We assessed the utility of a pharmacologic euglycemic clamp technique by examining the metabolic and hemodynamic changes brought about by administration of dihydroergotamine (DHE) prior to anesthesia and operative trauma in the rabbit. New Zealand white rabbits received an intramuscular injection of 0.15 mg DHE/kg body weight 20 minutes before general anesthesia and minor surgical trauma, which consisted of carotid artery and jugular vein catheterizations followed by femoral artery and vein cannulations. Arterial blood was sampled every 20 minutes and assayed for glucose, lactate, nonesterified fatty acids (NEFA), and insulin. Rates of hindlimb skeletal muscle glucose uptake (Rg) and blood flow were determined 2 hours after the initial administration of DHE. DHE did not produce any effects on heart rate, blood pressure, blood flow, and Rg when compared with control animals. Liver glycogen levels were significantly higher after DHE treatment (140 ± 31.4 v 34 ± 9.6 μmol/g dry weight, P<.01). Those animals receiving DHE had significantly lower and more stable plasma glucose levels than untreated animals (ranges, 5 to 9 v 7 to 22 μmol/mL plasma) and circulating NEFA were also lower and less variable (ranges, 0.1 to 1.0 v 0.1 to 2.0 μEq/mL plasma). The results show that DHE prevents stress-induced hyperglycemia in vivo in the rabbit without altering glucose uptake by skeletal muscle. The technique provides control over circulating glucose levels during the study of skeletal muscle glucose uptake without apparent negative physiologic effects.",
author = "Mossberg, {Kurt A.} and Heinrich Taegtmeyer",
year = "1991",
doi = "10.1016/0026-0495(91)90049-3",
language = "English (US)",
volume = "40",
pages = "594--599",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Dihydroergotamine as a pharmacologic euglycemic clamp in the surgically traumatized rabbit

AU - Mossberg, Kurt A.

AU - Taegtmeyer, Heinrich

PY - 1991

Y1 - 1991

N2 - We assessed the utility of a pharmacologic euglycemic clamp technique by examining the metabolic and hemodynamic changes brought about by administration of dihydroergotamine (DHE) prior to anesthesia and operative trauma in the rabbit. New Zealand white rabbits received an intramuscular injection of 0.15 mg DHE/kg body weight 20 minutes before general anesthesia and minor surgical trauma, which consisted of carotid artery and jugular vein catheterizations followed by femoral artery and vein cannulations. Arterial blood was sampled every 20 minutes and assayed for glucose, lactate, nonesterified fatty acids (NEFA), and insulin. Rates of hindlimb skeletal muscle glucose uptake (Rg) and blood flow were determined 2 hours after the initial administration of DHE. DHE did not produce any effects on heart rate, blood pressure, blood flow, and Rg when compared with control animals. Liver glycogen levels were significantly higher after DHE treatment (140 ± 31.4 v 34 ± 9.6 μmol/g dry weight, P<.01). Those animals receiving DHE had significantly lower and more stable plasma glucose levels than untreated animals (ranges, 5 to 9 v 7 to 22 μmol/mL plasma) and circulating NEFA were also lower and less variable (ranges, 0.1 to 1.0 v 0.1 to 2.0 μEq/mL plasma). The results show that DHE prevents stress-induced hyperglycemia in vivo in the rabbit without altering glucose uptake by skeletal muscle. The technique provides control over circulating glucose levels during the study of skeletal muscle glucose uptake without apparent negative physiologic effects.

AB - We assessed the utility of a pharmacologic euglycemic clamp technique by examining the metabolic and hemodynamic changes brought about by administration of dihydroergotamine (DHE) prior to anesthesia and operative trauma in the rabbit. New Zealand white rabbits received an intramuscular injection of 0.15 mg DHE/kg body weight 20 minutes before general anesthesia and minor surgical trauma, which consisted of carotid artery and jugular vein catheterizations followed by femoral artery and vein cannulations. Arterial blood was sampled every 20 minutes and assayed for glucose, lactate, nonesterified fatty acids (NEFA), and insulin. Rates of hindlimb skeletal muscle glucose uptake (Rg) and blood flow were determined 2 hours after the initial administration of DHE. DHE did not produce any effects on heart rate, blood pressure, blood flow, and Rg when compared with control animals. Liver glycogen levels were significantly higher after DHE treatment (140 ± 31.4 v 34 ± 9.6 μmol/g dry weight, P<.01). Those animals receiving DHE had significantly lower and more stable plasma glucose levels than untreated animals (ranges, 5 to 9 v 7 to 22 μmol/mL plasma) and circulating NEFA were also lower and less variable (ranges, 0.1 to 1.0 v 0.1 to 2.0 μEq/mL plasma). The results show that DHE prevents stress-induced hyperglycemia in vivo in the rabbit without altering glucose uptake by skeletal muscle. The technique provides control over circulating glucose levels during the study of skeletal muscle glucose uptake without apparent negative physiologic effects.

UR - http://www.scopus.com/inward/record.url?scp=0025800988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025800988&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(91)90049-3

DO - 10.1016/0026-0495(91)90049-3

M3 - Article

C2 - 1865822

AN - SCOPUS:0025800988

VL - 40

SP - 594

EP - 599

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 6

ER -